83% of Participants on Paltusotine Maintained IGF-1 ≤1.0 xULN vs. 4% on placebo (p<0.0001)
Mean IGF-1 Levels Were Maintained on Paltusotine vs. an Increase on Placebo (p<0.0001) After Switching from Injected Depot Standard of Care
Mean Acromegaly Symptom Diary Scores Were Maintained on Paltusotine vs. an Increase on Placebo (p=0.02) After Switching from Injected Depot Standard of Care
Paltusotine Was Well-Tolerated with No Severe or Serious Adverse Events
Management Will Host a Conference Call Monday, September 11, 2023 at 8:00 a.m. Eastern Time
Crinetics will hold a conference call and live webcast on Monday, September 11, 2023 at 8:00 a.m. Eastern Time to discuss topline results from the PATHFNDR-1 study. To participate, please dial 1-877-451-6152 (domestic) or 1-201-389-0879 (international) and refer to conference ID 13740941. To access the webcast, click here. Following the live event, a replay will be available on the of the Company’s website.
https://finance.yahoo.com/news/crinetics-once-daily-oral-paltusotine-140000136.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.